Journal of Neurology

, Volume 256, Issue 6, pp 910–915 | Cite as

Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism

  • Michele Tinazzi
  • Angelo Antonini
  • Tommaso Bovi
  • Isabella Pasquin
  • Maria Steinmayr
  • Giuseppe Moretto
  • Antonio Fiaschi
  • Sarah Ottaviani
Original Communication


We recently found that patients with drug-induced parkinsonism (DIP) may have normal (group I) or abnormal (group II) putamen [123I]FP-CIT DAT (dopamine transporter) binding. In this study we reassessed clinical features and DAT binding in 19 of the original 32 patients (10 of group I and 9 of group II) after a 19–39-month follow-up period and tested the effects of chronic levodopa treatment in both cohorts of patients. In group I patients, [123I]FP-CIT SPET (single photon emission tomography) was still normal in all patients at follow-up; DAT binding and UPDRS (Unified Parkinson’s Disease Rating Scale) motor score values did not differ from baseline. In group II patients, [123I]FP-CIT SPET was still abnormal at follow-up; putamen DAT binding was significantly reduced and UPDRS III score higher compared to baseline. Levodopa treatment improved motor symptoms in three out of ten patients of group I and in eight out of nine patients of group II. No adverse psychiatric effects were observed in any of the patients. This study shows that DAT binding imaging may help to identify subjects with DIP secondary to a loss of dopamine nerve terminals in the context of a progressive degenerative parkinsonism. Patients with DIP may benefit from levodopa therapy, particularly when dopamine nerve terminal defects are present, and this should be considered in the therapeutic management of these patients.


[123I]FP-CIT SPET Parkinson’s disease Drug-induced parkinsonism (DIP) Dopamine transporter (DAT) 


  1. 1.
    Alvarez MV, Evidente VG (2008) Understanding drug-induced parkinsonism: separating pearls from oy-sters. Neurology 70:32–34CrossRefGoogle Scholar
  2. 2.
    Angrist B, Sathananthan G, Gershon S (1973) Behavioural effect of l-dopa in schizophrenic patients. Psychopharmacologia 31:1–11PubMedCrossRefGoogle Scholar
  3. 3.
    Benamer HTS, Patterson J, Wyper D, Hadley DM, Macphee GJA, Grosset DG (2000) Correlation of Parkinson’s disease severity and duration with [123I]FP-CIT SPET striatal uptake. Mov Disord 15:692–698PubMedCrossRefGoogle Scholar
  4. 4.
    Booij J, Speelman JD, Hornstinkm M, Wolters EC (2001) The clinical benefit of striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with others forms of parkinsonism. Eur J Nucl Med 28:266–272PubMedCrossRefGoogle Scholar
  5. 5.
    Bower JH, Maraganore DM, McDonnel SK, Rocca WA (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 52:1214–1220PubMedGoogle Scholar
  6. 6.
    Burn DJ, Brooks DJ (1993) Nigral dysfunction in drug-induced parkinsonism: an 18 F-dopa PET study. Neurology 43:552–556PubMedGoogle Scholar
  7. 7.
    Davidson M, Keefe RSE, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL (1987) l-Dopa challenge and relapse in schizophrenia. Am J Psychiatry 144:934–938PubMedGoogle Scholar
  8. 8.
    Fleming P, Makar H, Hunter KR (1970) Levodopa in drug-induced extrapyramidal disorders. Lancet 2:1186PubMedCrossRefGoogle Scholar
  9. 9.
    Hardie RJ, Lees AJ (1988) Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51:850–854PubMedCrossRefGoogle Scholar
  10. 10.
    Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, Martin T, Litvinjuk Y, Giladi N (2001) Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 108:1299–1308PubMedCrossRefGoogle Scholar
  11. 11.
    Hausner RS (1983) Neuropleptic induced parkinsonism and Parkinson’s disease: differential diagnosis and treatment. J Clin Psychiatry 11:13–16Google Scholar
  12. 12.
    Hirose G (2006) Drug induced parkinsonism: a review. J Neurol 253(Suppl 3):III/22–III/24Google Scholar
  13. 13.
    Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R (2006) [123I] FP/CIT SPET imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord 21:510–514PubMedCrossRefGoogle Scholar
  14. 14.
    Miller LG, Jankovic J (1990) Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 8:525–532Google Scholar
  15. 15.
    Morrish PK, Sawle GV, Brooks DJ (1996) Regional changes in [18F]dopa metabolism in the striatum in Parkinson’s disease. Brain 119:2097–2103PubMedCrossRefGoogle Scholar
  16. 16.
    Ottaviani S, Tinazzi M, Pasquin I, Nothdurfter W, Tomelleri G, Fincati E, Nordera G, Moretto G, Fiaschi A, Smania N, Girogetti P, Antonini A (2006) Comparative analysis of visual and semi-quantitative assessment of striatal [123I] FP-CIT-SPET binding in Parkinson’s disease. Neurol Sci 27:397–401PubMedCrossRefGoogle Scholar
  17. 17.
    Pirker W (2003) Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 18(Suppl 7):43–51CrossRefGoogle Scholar
  18. 18.
    Scherfler C, Schwarz J, Antonini A, Grosser D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W (2007) Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 22:1229–1238PubMedCrossRefGoogle Scholar
  19. 19.
    Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Haldin C, Pilowsky LS, Pupi A (2002) European Association of Nuclear Medicine procedure guidelines for brain neurotrasmission SPET using (123)I-labelled dopamine (D2) transporter ligands. Eur J Nucl Med 29:BP30–BP35CrossRefGoogle Scholar
  20. 20.
    Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steimayr M, Vampini C, Pilleri M, Moretto G, Fiaschi A, Smania N, Giorgetti P, Antonimi A (2008) [123I] FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord 23:1825–1829PubMedCrossRefGoogle Scholar
  21. 21.
    Tolosa E, Coelho M, Gallardo M (2003) DAT imaging in drug induced and psychogenic parkinsonism. Mov Disord 18(Suppl 7):S28–S33PubMedCrossRefGoogle Scholar
  22. 22.
    Yaryura-Tobias JA, Wolpert A, Dana L, Merlis S (1970) The action of l-dopa on schizophrenic patients, a preliminary report. Curr Ther Res 12:528–531PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Michele Tinazzi
    • 1
    • 2
  • Angelo Antonini
    • 3
  • Tommaso Bovi
    • 1
  • Isabella Pasquin
    • 4
  • Maria Steinmayr
    • 5
  • Giuseppe Moretto
    • 2
  • Antonio Fiaschi
    • 1
  • Sarah Ottaviani
    • 2
  1. 1.Dipartimento di Scienze Neurologiche e della VisioneUniversità di VeronaVeronaItaly
  2. 2.Unita’ Operativa Neurologia OC Borgo TrentoVeronaItaly
  3. 3.Parkinson Institute, Istituti Clinici di PerfezionamentoMilanItaly
  4. 4.Unità Operativa di Medicina Nucleare OC Borgo TrentoVeronaItaly
  5. 5.Unita’ Operativa di Psichiatria OC Borgo TrentoVeronaItaly

Personalised recommendations